Conferences - Results from #9620

GU Cancers Symposium 2014 - Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)... January 31, 2014

GU Cancers Symposium 2014 - Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial - Abstract January 30, 2014

Dendreon announces presentation of PROVENGE® (sipuleucel-T) data at the 2014 Genitourinary Cancer Symposium (ASCO GU) January 30, 2014

GU Cancers Symposium 2014 - 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study - Poster January 30, 2014

GU Cancers Symposium 2014 - Newest-generation androgen therapies with radiation or surgery - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Peptide vaccines with low-dose dexamethasone versus dexamethasone alone for chemotherapy-naive castration resistant prostate cancer: A randomized phase II study - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Results of subset analyses on overall survival from study CA184-043: Ipilimumab (Ipi) versus placebo in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Beyond enzalutamide and abiraterone: What’s next in androgen therapy? - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Novel long noncoding RNA-dependent mechanisms of androgen receptor-regulated gene activation - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Unleashing the power of the immune system through combination therapy - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Dissecting the biology of the androgen receptor pathway - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study - Session Highlights January 30, 2014

Myriad's Prolaris® test significantly modifies treatment decisions for patients with prostate cancer January 29, 2014

Symposium highlights latest research advances in GU cancers January 28, 2014

GU Cancers Symposium 2014 - Premature termination of genitourinary cancer clinical trials - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Impact of angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII) - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Enzalutamide decreases risk of death and delays progression in phase III trial of men with metastatic prostate cancer - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study - Abstract January 25, 2014

Myriad Genetics to present five clinical studies at 2014 ASCO GU Cancer Symposium January 23, 2014

Page 482 of 524